Cargando…
Clinical Evidence of Cannabinoids in Migraine: A Narrative Review
The endocannabinoid system (ECS) influences many biological functions, and hence, its pharmacological modulation may be useful for several disorders, such as migraine. Preclinical studies have demonstrated that the ECS is involved in the modulation of trigeminal excitability. Additionally, clinical...
Autores principales: | Lo Castro, Flavia, Baraldi, Carlo, Pellesi, Lanfranco, Guerzoni, Simona |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949974/ https://www.ncbi.nlm.nih.gov/pubmed/35329806 http://dx.doi.org/10.3390/jcm11061479 |
Ejemplares similares
-
Spotlight on Anti‐CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date
por: Pellesi, Lanfranco, et al.
Publicado: (2017) -
Safety and Risk of Medication Overuse Headache in Lasmiditan and Second-Generation Gepants: A Rapid Review
por: Lo Castro, Flavia, et al.
Publicado: (2021) -
Increased efficacy of regularly repeated cycles with OnabotulinumtoxinA in MOH patients beyond the first year of treatment
por: Guerzoni, Simona, et al.
Publicado: (2016) -
OnabotulinumtoxinA: Still the Present for Chronic Migraine
por: Baraldi, Carlo, et al.
Publicado: (2023) -
Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy
por: Guerzoni, Simona, et al.
Publicado: (2017)